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Abstract. Near-infrared spectroscopy (NIRS) to monitor muscle oxygen saturation (SmO2) is rapidly expanding
into applied sports settings. However, the technology is limited due to its inability to convey quantifiable values.
A test battery to assess reliability and validity of a 0% to 100% scale modeled by a commercially available NIRS
device was established. This test battery applies a commonly used technique, the arterial occlusion method
(AOM) to assess repeatability, reproducibility, and face validity. A total of 22 participants completed the test
battery to scrutinize the 0% to 100% scale provided by the device. All participants underwent repeated
AOM tests in passive and active conditions. The SmO2 minimum and SmO2 maximum values were obtained
from the AOM and were used in the subsequent analysis. Repeatability and reproducibility were tested for equiv-
alency and Bland–Altman plots were generated. Face validity was assessed by testing SmO2 values against an
a priori defined threshold for mixed venous blood during AOM response. The device exhibits an appropriately
functional 0% to 100% scale that is reliable in terms of repeatability and reproducibility. Under the conditions
applied in the test battery design, the device is considered valid for application in sports. © The Authors. Published by
SPIE under a Creative Commons Attribution 4.0 Unported License. Distribution or reproduction of this work in whole or in part requires full attribution of
the original publication, including its DOI. [DOI: 10.1117/1.JBO.24.11.115001]
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1 Introduction
In recent years, muscle oxygen saturation (SmO2) measured via
near-infrared spectroscopy (NIRS) has developed into an afford-
able and readily available technology. The application of this
technology in athletic settings is expanding, as fundamental
questions are being addressed.1 One of the major concerns in
the application of NIRS in athletic settings is that common lim-
itations of NIRS are not well understood and need to be properly
addressed, while still allowing the technology to be utilized for
its clear advantages.2,3
The problem associated with using NIRS to measure quan-
tifiable values has been the unknown path length problem in the
modified Beer–Lambert method. Without knowing the photon
path length, it is impossible to derive quantifiable values from
the returning NIRS signal. This has the effect that NIRS output
is in relative values, most often expressed as arbitrary units
of hemoglobin (Hb) and myoglobin (Mb). NIRS cannot differ-
entiate between oxyhemoglobin (O2Hb) and oxymyoglobin
(O2Mb) or deoxyhemoglobin (HHb) and deoxymyoglobin
(HMb)4 and therefore for the remainder of this paper the terms
O2Hb and HHb will be the sum of O2Hb and O2Mb and HHb
and HMb. Because these arbitrary units are relative in nature,
direct comparisons are difficult and usually limited to trends
in the derived signal. To increase the robustness of the relative
values, it is often recommended to use a saturation in a percent-
age using the following equation:5,6
EQ-TARGET;temp:intralink-;sec1;326;412SmO2 ¼
O2Hb
O2Hbþ HHb
× 100.
Saturation takes into consideration the relative change of
total hemoglobin (tHb) and the interaction between O2Hb and
HHb. The result of this type of saturation equation is SmO2, as
mentioned earlier, or an often-applied tissue oxygenation index
(TOI). It is important to denote the difference between the two,
as they are often used interchangeably. In SmO2, the m indicates
that the saturation is intended be isolated to the muscle layer. In
TOI, the T indicates the measurement is an average of all tissues
under the sensor. Then, term saturation refers to the availability
and functionality of a 0% to 100% scale, whereas an index gen-
erally refers to a measurement ratio to be compared to a fixed
standard. If a parameter includes the term saturation, it should be
reliable and valid in terms of 0% to 100% scale. However, large
manufacturer differences, including inter-optode distance, num-
ber of wavelengths used, spectral width, and algorithmic calcu-
lations, all raise questions about the scaling of SmO2 and TOI.
7–9
These differences focus around interindividual and intersite
(muscle site selection) variation in results.10,11 When choosing
a new muscle site or changing test participant altogether, the
optical properties measured by the NIRS device changes. If the
NIRS device cannot adjust for these changes in specific meas-
urement site properties, a large variation is expected and seen.
Statistical normalization approaches, such as a physiological
calibration, are then often used to address these problems.7,9,12
The situation becomes even more complicated as no consen-
sus “gold standard” for NIRS-derived values exists to compare
against. Certain studies do refer to gold standard comparisons,
looking at alternate measurement techniques to validate NIRS.
*Address all correspondence to Andri Feldmann, E-mail: andri.feldmann@ispw
.unibe.ch
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Invasive experiments, such as isolated hindlimb experiments
with animal subjects13,14 or venous blood draw in humans
performing exercise protocols,15 show good results. Other
publications comparing NIRS measurements to invasive mea-
sures of blood oxygenation levels demonstrate lower levels
of success.16,17 Noninvasive phosphorus magnetic resonance
spectroscopy and NIRS comparisons18 also show good results.
Interesting, in particular, is the comparison between functional
magnetic resonance imaging (fMRI), which is noted by
Cui et al.19 as a gold standard in human brain imaging and
NIRS. FMRI as blood oxygen-level-dependent imaging requires
the user to make almost near-identical assumptions about the
measurement technique being used as NIRS does.6 When debat-
ing a specific gold standard to which NIRS-derived SmO2
should be compared, an obvious lack of authority exists as the
term is not mentioned in reviews,6,20,21 with appropriate hesita-
tion. Alternate methods are needed to address the question of
validity of SmO2 measurements on a 0% to 100% scale.
A technique used for addressing the difficulty of relative
values provided by NIRS, including the interindividual and
intersite measurement dilemma, is the normalization process of
physiological calibration.20,21 This technique applies the arterial
occlusion method (AOM) to identify the minimum and maxi-
mum signals of the NIRS device in question. The AOM func-
tions by applying a suprasystolic cuff to a chosen limb for a 5- to
6-min period, which results in a linear change in the NIRS-
derived signal for O2Hb to a minimum signal point identified
by a plateau. Upon release, the phenomenon of hyperemia22
results in a return of the NIRS signal to a maximum point; the
opposite is true for HHb. The minimum signal is a maximally
deoxygenated state defined by a disappearance of O2Hb in rela-
tion to the sum of O2Hb and HHb, and maximum signal is a
maximally oxygenated state and the disappearance of HHb to
the sum O2Hb and HHb. Having identified the minimum and
maximum points, these can then be set at 0% to 100% as a
physiological calibration. This process generates an individual
and robust scale for further testing. Considering the debate
around a true gold standard, this type of physiological calibra-
tion offers a functional test to assess and compare NIRS devices
and SmO2 scaling. In athletic settings and other possible appli-
cations of NIRS, using a standard AOM to calibrate the NIRS
signal for each measurement site is not a feasible approach.
Therefore, an NIRS device that provides a reliable and valid
0% to 100% scale with reasonable accuracy would greatly
enhance NIRS usability.
To address the question of validation and reliability of an
NIRS device, three concepts should be applied:
1. Repeatability23 refers to closeness of agreement
between repeated measurements made on the same
participant under identical conditions.
2. Reproducibility23 refers to the closeness of agreement
between repeated measurements made under changing
conditions. Under this rubric, three underlying con-
cepts can be addressed: the intersite and interindivid-
ual differences discussed early, as well as change
in muscle activation from a passive AOM test to an
AOM test under active conditions or interactivation
differences. These approaches have been examined
using NIRS,24,25 including a study by Lacroix et al.26
using the AOM to investigate the NIRS reproducibility
during brachial artery occlusions yielding a high
degree of reproducibility.
3. Face validity27 refers to the reasonable expectation of
measurements taken based on selected criteria. This
last approach presumes to address the question of
physiological validity, which is difficult to answer
using NIRS. A possible criterion to setup thresholds
to test against is a measure of venous oxygen satura-
tion (SvO2).
This paper applied the three identified concepts above in a
specific test battery to evaluate the performance of SmO2 on
a scale of 0% to 100% provided by a commercially available
NIRS device, the Moxy Monitor.
2 Methods
2.1 Participants
A total of 22 participants, 11 males and 11 females, took part in
the study {age 21.8 1.6 years; height 173.3 9.9 cm; weight
67.0 10.7 kg ½mean standard deviationðSDÞ}. All partici-
pants were Caucasian, in good health, nonsmokers, and unmedi-
cated. Skinfold measures were taken using skinfold calibers to
assess adipose tissue thickness (ATT) at the four measurement
sites: vastus lateralis (VL) 12.5 5.1 mm; rectus femoris (RF)
13.9 5.3 mm; vastus medialis (VM) 13.3 6.1 mm; gastroc-
nemius (G) 11.1 5.9 mm. The participants were informed of
the study design and the physical tasks ahead of time and written
informed consent was obtained in advance. The study was car-
ried out in accordance with the 1964 Declaration of Helsinki.
The protocol was approved by the ethics committee of the local
Faculty of Human Sciences.
2.2 Moxy Monitor
The Moxy Monitor (Fortiori Design LLC) is an NIRS device
that propagates to provide an a priori 0% to 100% scale with
accuracy useful for sports science applications. The device mea-
sures the amount of light reaching two detectors from one emit-
ter at four wavelengths in a diffuse reflectance configuration for
a total of eight measurements. The device detectors are spaced at
12.5 and 25 mm from the emitter. The default sampling rate
cycles through the four wavelengths 80 times every 2 s and aver-
ages out the readings for an output rate of 0.5 Hz. As the device
in focus, which propagates to provide an a priori 0% to 100%
scale with reasonable accuracy, a clearer picture of the technical
process involved to isolate and investigate the muscle layer and
generate an SmO2 output is provided. This should highlight the
process with which this continuous wave device is able to over-
come the path length problem and return absolute saturation
values. However, perhaps of greater importance in determina-
tion of absolute saturation values and a focus of this paper is that
the data output acquired through standardized experimentation
should be assessed to determine reliability and validity, rather
than technical approaches to the path length problem.
The measurement algorithm uses four steps to overcome the
unknown path length problem:
1. The device applies a Monte Carlo model28,29 to gen-
erate a large set of optical rays over the full measure-
ment spectrum that travel from the emitter to the
detectors through the predetermined tissue layers
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consisting of epidermis, dermis, adipose, and muscle.
The model uses published values30–33 for scattering in
these tissue types. The ray data include the path length
in each layer and the model is run for numerous differ-
ent ATT layers.
2. A data smoothing application is applied to reduce the
effects of Monte Carlo statistical errors.
3. A matrix of expected detector measurements is gener-
ated from the ray trace data based on tissue optical
properties that are expected to be encountered when
measuring athletes, including the expected ranges of
SmO2 and tHb. This uses published values
30–33 for the
absorbance of the chromophores that are modeled in
each tissue layer.
4. A numerical solving and interpolating algorithm that
compares the eight actual diffuse reflectance measure-
ment matrices from step 3 to determine the optical
properties (i.e., SmO2 and tHb) of the muscle layer is
applied.
The following equation shows how steps 1 to 3 are used to
generate the matrix of expected detector measurements by
applying the Beer–Lambert relationship to the Monte Carlo ray
trace data:
EQ-TARGET;temp:intralink-;sec2.2;63;465
I ¼ fq
Xλ¼high
λ¼low
Xmλ
i¼1
Sλj0;λ;sampΔλ
nλ
× e−ðμA;e;λLe;λ;iþμA;d;λLd;λ;iþμA;a;λLa;λ;iþμA;m;λLm;λ;iÞ;
where I is the total intensity of the optical detector output; f and
q are the scaling parameters for wavelength-independent factors
such as the optical coupling efficiency to the tissue and the LED
brightness; the first summation is over the wavelength range of
the light source; the second summation is over all rays that were
traced to reach the detector; Sλ is the spectral sensitivity of the
detector; j0;λΔλ∕nλ is the initial power in each ray; μA is the
absorption coefficient, which is the sum of the absorption coef-
ficients of all relevant chromophores; L is the total path length in
that layer of the i’th ray; and the subscripts e, d, a, andm refer to
the tissue layers of epidermis, dermis, adipose, and muscle,
respectively.
There are several important factors in this algorithm that
attempt to overcome the limitations of the traditional modified
Beer–Lambert techniques.
1. The Monte Carlo model accommodates the wave-
length-dependent scattering differences across the
measurement spectrum. The model returns the path
length for each ray in each of the tissue layers to
overcome the unknown path length problem of the
Beer–Lambert law.
2. The Monte Carlo model includes the effects of an
unknown ATT by modeling a range of ATT. A differ-
ent set of ray trace data is used for each ATT in gen-
erating the matrix of expected detector measurements.
3. More subtly, the effective path length (EPL), even for
a fixed set of traced rays with a distribution of path
lengths, is dependent on the absorbance. In the limit of
absorbance approaching infinity, the EPL approaches
the shortest path lengths in the distribution. In the limit
of absorbance approaching zero, the EPL approaches
the average path length of the distribution. The model
overcomes this complexity by using the full ray trace
set for all detector measurement predictions.
4. The model includes confounding factors, such as
melanin, water, LED spectral width, and varying
detector spectral sensitivity, which accommodate their
presence in the measurement and allow the wavelength
selection and solving algorithms to be designed to
minimize sensitivity to these factors.
5. The algorithm includes the LED spectral sensitivity to
temperature, which is accommodated by a temperature
sensor in the device.
The Moxy Monitor has been compared with alternate NIRS
device and evaluated for reliability and validity in previously
published papers.7,34
2.3 Near-Infrared Spectroscopy Measurement
The sensors were mounted on four muscles, ensuring that min-
imal spacing between interdevice receiver and detector of 10 cm
was maintained to avoid interference. The first sensor was
placed on the VL at two-thirds between anterior superior iliac
spine and the lateral side of the patella. The second sensor was
placed on the RF half way between the anterior superior iliac
spine and the top part of the patella. The third sensor was placed
on the VM four-fifth down along the line of the anterior superior
iliac spine and anterior border of the medial ligament. The final
sensor was placed on the lateral head of the G at one-third of the
way between the head of the fibula and the heel. All locations
are as recommended by the SENIAM project35 for electromyog-
raphy measurements. The emitter and detectors were aligned in
the direction of muscle fibers, and body hair was removed from
the sensor sites. The sensors were fixed in place using medical
adhesive tape (Hypafix; BSN Medical, DE) and were then
covered with the compatible commercially available light shield
to eliminate possible ambient light intrusion.
2.4 Procedure
A series of tests were selected to address the questions of reli-
ability and validity on a 0% to 100% scale generated by the
selected NIRS device. The test battery was designed to examine
repeatability, reproducibility, and face validity. To limit the
physiological variation and ensure a stable and repeatable
environment, all tests used the AOM. For the experimental
procedure, participants came into the lab for two session with
1-week separation between each session, as shown in Fig. 1.
2.4.1 Arterial occlusion method
The AOM was conducted using a pneumatic tourniquet (Rudolf
Riester GmbH, DE) with thigh cuff dimensions of 96 × 13 cm
inflated to >300 mmHg. The tourniquet was suited on the right
leg of all the participants. Prior to every test, all participants
were asked to refrain from strenuous physical activity 24 h prior,
to refrain from alcohol consumption and smoking 24 h prior
to the experiment, and to maintain individual diet routine.
The maximally deoxygenated state plateau identified as SmO2
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minimum (SmO2 min) was determined by the average of the
final 20 s or 10 data points of the AOM, as long as this met
the condition of a visual plateau. The maximally oxygenated
state identified as SmO2 maximum (SmO2 max) was determined
as the peak SmO2 output average over 10 s or 5 data points
following the end of the AOM as a result of the hyperemic
effect.
2.4.2 Passive trials
Sensors were placed on the VL, VM, RF, and G and the partic-
ipants assumed a lying supine position. Participants assumed
the lying position for 5 min prior to data collection. The data
collection started with 60 s of data collection for a baseline
measurement, and after 60 s the pneumatic tourniquet was rap-
idly inflated. The pneumatic tourniquet remained inflated and
pressure controlled for the 6 min to find the SmO2 min plateau.
The quality of the arterial occlusion was controlled through
pulse oximeter and pulse palpation of the lower leg. After 6 min,
the pneumatic tourniquet was released, and an additional 3 min
of measurement took place to assess the hyperemic response and
to find the SmO2 max value.
2.4.3 Active trial
Each participant came in for an initial setup session to determine
1 repetition-maximum (1-RM). Participants executed a series of
maximum effort leg extension trials on a leg extension machine
(Schnell GmbH, DE). The best trial was taken as their estimated
1-RM. In the active AOM session, each participant was again
suited with the pneumatic tourniquet and the sensors placed
on the activity-recruited muscles VL, VM, and RF. The partic-
ipants were then positioned in the knee extension machine and
remained in the sitting position for 5 min prior to data collection.
The data collection started with 60 s of data collection for a
baseline measurement and, after the 60 s, the pneumatic tourni-
quet was rapidly inflated. The participants then executed con-
tinuous leg extension repetitions at 40 rpm at 5% of 1-RM
until exhaustion. The pneumatic tourniquet remained inflated
and pressure controlled as long as activity took place to identify
SmO2 min. Following exhaustion, the pneumatic tourniquet was
released, and an additional 3 min of measurement took place to
assess the hyperemic response and to find the SmO2 max value.
2.5 Statistical Analysis
Owing to the confounding effects of ATT,36 all measurement
sites with ATT greater than 60% of the emitter-detector distance
(15.0 mm) were removed from the analysis. The Shapiro–Wilk
test was selected for all data sets to test for normal distribution
because of the small sample sizes used in the study. Statistical
computations were performed using Microsoft Excel for
Windows (Version 16.0.4738.1000) and MathWorks Matlab for
Windows (Version 9.3.0.713570 R2017b). Equivalency testing
was used as the groundwork for statistical procedure based
on the confidence interval (CI) comparisons and a priori
equivalency intervals (EIs) to determine statistical equivalency
and statistical difference in accordance with studies by Lakens37
and Cumming and Finch.38 The a priori determined EI for
SmO2 was set at 5%.
2.5.1 Repeatability, interindividual, and intersite
reproducibility: passive trials
To assess device repeatability, a Bland–Altman plot39 was
constructed for the two extracted values of SmO2 max and
SmO2 min for all four repeated measurement sites: VL, VM,
RF, and G. Upper and lower limits of agreement were set at
1.96 SD and 95% CIs were calculated. An EI was set at
5%. Pearson’s correlation coefficients were calculated and
tested for significance to assess the relationship between mean
and mean difference. For interindividual and intersite reproduc-
ibility, all means and mean differences were plotted for all
muscle sites with 90% CI and 95% CI for equivalency testing.
2.5.2 Interindividual, intersite, and interactivation
reproducibility: active trial
The attainable values for SmO2 min and SmO2 max for the
active and passive conditions were displayed in a Bland–
Altman plot39 to determine the interactivation reproducibility for
VL, VM, and RF. Upper and lower limits of agreement were set
at 1.96 SD and 95% CI were calculated. The same EI was set
at 5%. Pearson’s correlation coefficients were calculated and
tested for significance to assess the relationship between mean
and mean difference. For interindividual and intersite reproduc-
ibility, all means and mean differences were plotted for all
muscle sites with 90% CI and 95% CI for equivalency testing.
For the calculations, the mean of the Moxy passive trials was
used against the corresponding active trial and therefore proper
adjustments to SD were made as proposed by Bland and
Altman.40
2.5.3 Face validity: 0% to 100% scale
To determine face validity, a comparison was made between
SmO2 results from the AOM passive Moxy trials and docu-
mented values for SvO2 post AOM tests. Hamaoka et al.’s
Fig. 1 Experimental procedure and aim for each participant. The test battery involved two AOM test
sessions including two passive AOM trials and one active AOM trial.
Journal of Biomedical Optics 115001-4 November 2019 • Vol. 24(11)
Feldmann, Schmitz, and Erlacher: Near-infrared spectroscopy-derived muscle oxygen. . .
Downloaded From: https://www.spiedigitallibrary.org/journals/Journal-of-Biomedical-Optics on 18 Nov 2019
Terms of Use: https://www.spiedigitallibrary.org/terms-of-use
results41 show an end AOM value for SvO2 of 26.2 6.4%.
Langham et al.’s results42 show an end AOM hyperemic value
for SvO2 of 85 8.0%. These values were used to establish a
priori thresholds for SmO2 max and SmO2 min for comparison
with the results of the AOM passive trials. Means for all muscle
sites SmO2 max and SmO2 min with 90% CI and 95% CI were
plotted against the a priori thresholds to assess difference.
3 Results
All muscle sites display the expected linear decrease in SmO2
with the application of the suprasystolic cuff to a minimum pla-
teau and upon release a hyperemic response in both passive and
active conditions (see Fig. 2). The 0% to 100% scale showed
a good dynamic range over all muscle sites during passive
conditions with Mrange of 67.9% 9.9 (Mmin ¼ 10.1% 5.7;
Mmax ¼ 78.1% 6.0), as shown in Fig. 3.
3.1 Repeatability, Interindividual, and Intersite
Reproducibility: Passive Trials
Looking at the mean difference of SmO2 min, repeatability dur-
ing passive trials in all muscle sites showed no statistical differ-
ence between passive trials 1 and 2 and all can be considered
statistically equivalent using EI (see Fig. 4). For SmO2 max,
repeatability during passive trials all muscle sites showed no
statistical difference between passive trials 1 and 2, but only the
VL and G sites can be considered statistically equivalent
(Fig. 4). Bland–Altman plot analysis was used in addition to
assess equality on a case-to-case basis. All Bland–Altman
results were considered to show suitable agreement between
passive trials 1 and 2 (Fig. 5). All muscles show no systemic
bias between trials 1 and 2, as the line of equality is clearly
within the EI. The data show that the SmO2 max hyperemia has
a greater degree of variation than SmO2 min as a result of the
AOM (Fig. 5). However, none of the plots shows significant
relationship between mean and difference in both the max and
min responses following a Pearson product–moment correla-
tion. Looking at the mean of SmO2 min and SmO2 max for inter-
individual and intersite reproducibility during passive trials, no
statistical difference between the obtained values can be dis-
cerned (Fig. 2).
3.2 Interindividual, Intersite, and Interactivation
Reproducibility: Active Trial
Looking at reproducibility between active trials and passive
trials, mean difference comparisons show no difference and stat-
istical equivalency between VL SmO2 min and VM SmO2 min
Fig. 2 Predicated linear decrease in SmO2 as a result of the AOM and time during (a) passive and
(b) active conditions, with minimum value plateau and hyperemic response on cuff release. Dotted lines
indicate start and stop of the AOM. Mean VL (○); mean VM (⋄); mean RF (▵); mean G (x).
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using the EI (see Fig. 4). The same is true for VL SmO2 max.
RF SmO2 max and VM SmO2 max showed no difference but
are not statistical equal (see Fig. 4). RF SmO2 min was not sta-
tistically equivalent and different at the 95% CI. The results of
SmO2 max and SmO2 min on a Bland–Altman plot for the three
examined quadriceps muscle sites show acceptable equivalency
for VL and VM but not for RF between passive and active trials
(see Fig. 6). As with the comparison between passive trials, the
active–passive trials show a greater degree of variation in the
SmO2 max hyperemia results. Unlike the passive trial compari-
son, the active-passive trials show a significant relationship
between mean and difference for SmO2 min in a Pearson prod-
uct-moment correlation with a tendency toward higher values
for SmO2 min for the active condition for VL SmO2 min
(r ¼ −0.5251, n ¼ 15, p ¼ 0.044) and RF SmO2 min [r ¼
−0.7071, n ¼ 13, p ¼ 0.006 (see Fig. 6)]. Looking at the
mean of SmO2 min and SmO2 max for interindividual and inter-
site reproducibility, during active and passive trials only RF
SmO2 min during the active trial shows potential difference
in means (see Fig. 2).
3.3 Face Validity: 0% to 100% Scale
The a priori determined thresholds for SmO2 min and
SmO2 max were tested against the mean of trials 1 and 2.
For each muscle site, the passive trial mean was plotted with
90% CI and 95% CI and assessed against the a priori thresholds.
With the exception of RF SmO2 min, during active conditions
all means for SmO2 min and SmO2 max lie below the a priori
thresholds as predicted (see Fig. 2). RF SmO2 min crosses the
threshold at the 95% CI.
3.4 Effect of Adipose Tissue Thickness
Because of the well-documented effects of ATT on NIRS signal
and consequently on SmO2, the effect of ATTon SmO2 min was
plotted for each muscle site using all 22 participant’s data (see
Fig. 7). Linear and segmented regressions were calculated for
each muscle site. Clearly, a relationship exists between ATT
and SmO2 min, as shown by the linear regression for all muscle
sites: VL (r ¼ 0.844, n ¼ 22, p < 0.001); VM (r ¼ 0.901,
n ¼ 22, p < 0.001; RF (r ¼ 0.872, n ¼ 22, p < 0.001); and
G (r ¼ 0.912, n ¼ 22, p < 0.001). When using a segmented
regression, all muscle sites identify a single knot at 15.37
1.52 mm to optimize the linear regression (see Fig. 7). The
results indicate to a certain degree an effectiveness in maximiz-
ing the sensitivity of the NIRS-derived SmO2 signal as long as
the ATT thickness remains within the recommended penetration
depth threshold of 15 mm. SmO2 values obtained over the ATT
threshold should be considered suspect.
4 Discussion
The purpose of this experiment was, first, to propose a test
battery to investigate reliability and validity of SmO2 on 0% to
100% scale and, second, to apply this test battery to readily
available NIRS device. The argument presented makes some
assumptions, the first of which is that the process of
a physiological calibration through AOM provides reliable and
functional information about the range of NIRS-derived oxy-
genation signals at an individual level. This being true, a reliable
and valid 0% to 100% scale can be scrutinized using the AOM.
The 0% to 100% scale tested would need to show acceptable
results for repeatability, reproducibility, and face validity, and
therefore this test battery sets the groundwork to determine
device functionality. In this experiment, all participants showed
good repeatability and reproducibility during the AOM tests
using the Moxy Monitor.
To discuss validity, an inference was made, and therefore as a
product of deductive reasoning the term face validity was con-
sidered appropriate. The first position was that muscle tissue
during activity or occlusion situations would represent the high-
est metabolic activity in comparison to other peripheral tissue
being measured.43 Therefore, when comparing NIRS-derived
values for SmO2 against invasive measures of SvO2, the SmO2
values cannot be higher than the measured value for SvO2.
SmO2 should be lower, as SvO2 is a combination of venous
blood returning from all tissue layers, including adipose and
skin tissue; this is the premise of venous blood contamination,
which will be discussed later. While this does not establish val-
idity of an NIRS-derived SmO2 value, it does establish thresh-
olds against which measured values can be tested and lends
a useful SmO2 range; the same argument is made by McManus
et al.7 The a priori SvO2 thresholds applied to this study are
Fig. 3 Mean (black squares) and 90% CI (thick darker vertical lines)
and 95% CI (thin lighter vertical lines) for SmO2min and SmO2max
for (b) active and (a) passive conditions for all muscle sites: VL, VM,
RF, and G. Dashed lines indicate the a priori determined thresholds of
SvO2 for assessment of face validity.
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drawn from SvO2 data collected during AOM experiments and
show the extent of oxygenation ranges in metabolic tissue.41,42
This range has also been established during high-intensity
exercise, during small muscle activation, and during full body
exercise. Costes et al.16 showed SvO2 values of 17.8 4.2 and
7.8 2.3 in normoxia (N) and hypoxia (H), respectively,
following 20 min of steady-state cycling at 80% of VO2 max.
Mancini et al.15 and Macdonald et al.17 showed SvO2 ranges
following small muscle and lower body isolated kicking exer-
cises of 30.4 6.8%, and then 40.1 2.2 (N) and 33.9 1.8
(H). All three of these investigations included NIRS measure-
ments. While for Mancini et al.15 the NIRS data collected
correlated with the SvO2 data, for both Costes et al.
16 and
Macdonald et al.17 this was not the case under the normoxic con-
dition. This confounds the relationship between NIRS-derived
oxygenation signals and SvO2. A reconciliation with these ap-
parent contradictions involves the venous blood contamination
problem discussed earlier.6 Measured SvO2 is a combination of
blood from active skeletal muscles and skin and adipose tissue
circulation. The venous blood contamination problem then
results in increased or contradictory NIRS values, in comparison
to SvO2, because of increased contribution of lower metaboli-
cally active tissue to the NIRS signal as a result of, for example,
skin blood flow increase for heat dissipation.44,45 Advancements
in the spatially resolved method has attempted to address this
problem.45 While this advancement has helped in the scaling
of NIRS, when looking at device comparison data from this
experiment, or alternative studies,7–9 clearly a functional scale
has not been determined. A device measuring SmO2 must dis-
tinguish between measured tissue layers to isolate the muscle
layer. This is particularly important because certain NIRS devi-
ces provide a TOI measurement rather than a SmO2 measure-
ment. This difference should be considered in the analysis and
discussion of NIRS data, as the two terms should not be used
interchangeably.
To further address and discuss this useful accuracy of SmO2,
assumptions about signal contribution need to be made. Under
normal conditions, muscles receive near completely oxygenated
arterial blood8 and therefore it can be assumed changes in
oxygenation reported by the NIRS signal can be attributed to
changes in Hb and Mb oxygenation at the examined tissue level.
The physical demands of the Beer–Lambert law exempt large
blood vessels from contributing in a significant way to the
NIRS-derived signal, as the concentration of absorbing chromo-
phores is too large to return a signal.6 This means that the NIRS-
derived signal is mostly from smaller vessel contributions along
the lines of arterioles, capillaries, and venules. How much of
the signal is derived from which source is a discussion,46–48 and
a commonly used formula is equal parts contribution by all
three-vessel systems7 or the “one-third, one-third, one-third”
model. This assumption led to the discussion by McManus
et al.7 that the range of SmO2 by the Moxy Monitor is rather
large. Interestingly, McManus et al.7 apply the same logic using
SvO2 thresholds to discuss a potential physiological validity,
just applying a different assumption of contribution. The paper
does go on to discuss potential difference in NIRS signal as a
result of muscle layer specialization—stressing the importance
of terminology between for TOI and SmO2. Nonetheless, the
one-third, one-third, one-third model stands to be disputed.
Boushel et al.47 argue for a 10∶20∶70 ratio of arterial, capillary,
and venous blood in the NIRS signal. An experiment by
Poole and Mathieu-Costello48 shows that >90% of total blood
volume in the muscles is in the capillaries, which would then
again return to the question of tissue layer isolation when talking
about signal contribution. Clearly, the one-third, one-third,
one-third model for signal contribution is questionable and
an adequate model is up for debate. As this paper has no
experimental claim to credit or discredit magnitude of signal
contribution as was discussed, the assumption that a device
advocating a 0% to 100% scale of reasonable accuracy in the
form of physiological validity for SmO2 should have results that
are smaller than the measured values of SvO2 remains intact as
a matter of deduction.
Fig. 4 Mean differences (black squares) and 90% CI (thick darker horizontal lines) and 95% CI (thin
lighter horizontal lines). The mean differences for active and passive trials are the difference between
passive trials mean and the active trial in question. A priori EI is set at 5% (dashed lines). Solid line
indicates line of equality.
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4.1 Limitations
The conducted experiment has its limitations, first and foremost
in the assumptions that are repeatedly discussed. These assump-
tions stand to be refuted. The assumption of the SvO2 thresholds
relies on third-party data collections and therefore the question
of comparison needs to be addressed. Both papers cited41,42 use
similar population pools and apply the same AOM to determine
maximum and minimum values. For this reason, it was deter-
mined to be suitable to use these data to bridge the question
Fig. 5 Bland–Altman plots of passive trials 1 and 2 for SmO2min and SmO2max for (a) VL, (b) VM,
(c) RF, and (d) G. A priori EI is set at 5% (shaded area). The solid line identifies the mean bias
(MB) and dashed lines identify the upper and lower limits of agreement at 1.96 SD. For both the
MB and the limits of agreement, respectively, dotted lines represent 95% CI.
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of physiological validity. It is highly recommended that this
experiment is duplicated with venous blood sampling or
alternative forms of physiological validation. The participant
pool suffers from a large degree of homogeneity in terms of
age, activity level, and melanin content (all participants were
Caucasian). Further data need to be collected on differing dem-
ographic groups. ATT is a major concern for NIRS, as shown in
this paper by the exclusion of measurement sites used in the
analysis due to ATT. Caution is recommended when using the
Moxy Monitor with ATT >15 mm. As identified in Sec. 4,
arterial blood is always nearly completely oxygenated prior
to the AOM. This study does not look at what would happen
if you were to manipulate arterial oxygen saturation prior to the
AOM. Generally, the SmO2 min and SmO2 max data appear to
be consistent across muscle sites, individuals, and during mus-
cularly active and passive conditions, there is some deviation in
the RF between active and passive conditions. This identifies
further need for trials and investigation. This may be the result
of the effect of position and occlusion cuff during the knee
extensions, muscle requirement, and a greater degree of individ-
ual physiological variation during hyperemia. As can be seen in
the Bland–Altman plots (see Fig. 6), the RF during the active
conditions has a few substantial outliers. Outliers were not
removed for transparency purposes. Finally, for the statistical
analysis of SmO2 min and SmO2 max, averages were collected
for the identifiable plateaus and limits. Considering the low sam-
pling rate of the device, these calculations involved a small num-
ber of data points, which should be concerning, as they are
subject to noise, as is any measurement. However, as pointed
out in the device specifications, while it is correct that the sam-
pling rate in terms of received data is 0.5 Hz, this output value is
already a product of smoothing over 80 LED cycles. Therefore,
Fig. 6 Bland–Altman plots of passive trials mean and active trials for SmO2min and SmO2max for (a)VL,
(b) VM, and (c) RF. A priori EI is set at 5% (shaded area). The solid line identifies the MB and dashed
lines identify the upper and lower limits of agreement at 1.96 SD. For both the MB and
the limits of agreement, respectively, dotted lines represent 95% CI. For RF SmO2min and VL
SmO2min, a significant relationship was found between mean and mean difference (diagonal correlation
line) at R2 ¼ 0.2727 and R2 ¼ 0.4999, respectively.
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the output information has already been, to a certain extent, con-
trolled for noise as it is a product of a much larger sampling rate.
Still, while considerations were made, time course components
of the NIRS parameters were left out of the analysis because of
the 0.5-Hz output rate.
5 Conclusion
The study illustrates that the retail NIRS device Moxy Monitor
is valid and reliable under the conditions of the test battery used.
The validity attributed to the device in this paper is a conse-
quence of a series of assumptions, which should be viewed criti-
cally. While the repeatability and reproducibility comparison
were successful and the functionality of NIRS to measure
changes in SmO2-related supply-and-demand parameters does
not stand in question, the validity of a 0% to 100% scale is open
for discussion. Nonetheless, this type of scaling is of great
importance for research and athletic applications in order to
compare and contrast data. For this reason, the authors recom-
mend the use of functional scales of 0% to 100% that reflect to
an acceptable degree physiological validity, in this case to the
reference to SvO2. In the absence of a gold standard, functional
scales should be tested in the form of physiological calibration
via AOM involving this type of testing battery, including tests of
repeatability, reproducibly, and validity.
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